KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2025)

Historic EBT Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 3135.27%.

  • Recursion Pharmaceuticals' EBT Margin fell 27684400.0% to 3135.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 1638.15%, marking a year-over-year decrease of 10506600.0%. This contributed to the annual value of 789.93% for FY2024, which is 448300.0% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' EBT Margin stood at 3135.27%, which was down 27684400.0% from 894.23% recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' EBT Margin ranged from a high of 366.82% in Q3 2024 and a low of 3935.31% during Q4 2024
  • Moreover, its 5-year median value for EBT Margin was 891.18% (2023), whereas its average is 1267.8%.
  • Per our database at Business Quant, Recursion Pharmaceuticals' EBT Margin skyrocketed by 293818100bps in 2021 and then tumbled by -30441300bps in 2024.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' EBT Margin stood at 2564.55% in 2021, then surged by 83bps to 445.91% in 2022, then plummeted by -100bps to 891.18% in 2023, then tumbled by -342bps to 3935.31% in 2024, then rose by 20bps to 3135.27% in 2025.
  • Its last three reported values are 3135.27% in Q3 2025, 894.23% for Q2 2025, and 1374.33% during Q1 2025.